Objectives:~Primary objective:~•To determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy.~Secondary objective:~• To assess the recurrence free survival and overall survival in treated patients in order to make initial assessment of activity of this therapeutic approach~Exploratory Objectives:~• To quantitate immune responses in patients who receive autologous DCs loaded with tumor lysate plus mRNA
To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma